Clinical Practice Guidelines for the Management for the Evaluation, Classification and Stratification of Chronic Kidney Disease


**Definition of Chronic Kidney Disease (CKD)**
- Chronic kidney disease is defined as a glomerular filtration rate or GFR <60 mL/min/1.73m² for ≥3 months with or without kidney damage. Kidney damage is defined as structural or functional abnormalities of the kidney, with or without decreased GFR, as manifested by either pathologic abnormalities or markers of kidney damage (proteinuria, hematuria, pyuria, abnormal imaging studies). GFR can be estimated (eGFR) using the serum creatinine and one of several formulas.

**National Kidney Foundation Classification of Chronic Kidney Disease**
- Stage 1=Kidney damage with normal or increased GFR (≥90); Clinical presentations include nephrotic syndrome, nephritic syndrome, tubular syndromes, urinary tract syndromes, asymptomatic urinary or radiologic abnormalities, hypertension due to kidney disease. Diagnose and treat kidney disease and comorbid conditions to slow progression and reduce cardiovascular disease (CVD) risk.
- Stage 2=Kidney damage with mild or decreased GFR (60-89); May present with mild complications. Estimate progression.
- Stage 3=Moderately decreased GFR (30-59); May present with moderate complications. Evaluate and treat complications by assessing presence of anemia, nutritional status, bone metabolism and indices of functioning and well being.
- Stage 4=Severely decreased GFR (15-29); May present with severe complications. Refer to nephrologists and prepare for kidney replacement therapy (KRT).
- Stage 5=Kidney failure (GFR<15 or dialysis); May present with uremia and cardiovascular disease. Requires KRT.

**Factors Affecting Individuals at Increased Risk for Chronic Kidney Disease**

<table>
<thead>
<tr>
<th>Clinical factors</th>
<th>Sociodemographic factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>Older age</td>
</tr>
<tr>
<td>Hypertension</td>
<td>U.S. ethnic minorities</td>
</tr>
<tr>
<td>Autoimmune diseases</td>
<td>African American, Native American, Hispanic, Asian or Pacific Islander)</td>
</tr>
<tr>
<td>Systemic infections</td>
<td>Exposure to certain chemical and environmental conditions</td>
</tr>
<tr>
<td>Urinary tract infections or stones</td>
<td>Low income / education</td>
</tr>
<tr>
<td>Lower urinary tract obstruction</td>
<td></td>
</tr>
<tr>
<td>Neoplasia</td>
<td></td>
</tr>
<tr>
<td>Family history of CKD</td>
<td></td>
</tr>
<tr>
<td>Recovery from acute kidney failure</td>
<td></td>
</tr>
<tr>
<td>Reduction in kidney mass</td>
<td></td>
</tr>
<tr>
<td>Exposure to certain drugs</td>
<td></td>
</tr>
<tr>
<td>Low birth weight</td>
<td></td>
</tr>
</tbody>
</table>

**Association of CKD with Cardiovascular Disease**
- Patients with CKD are at increased risk of CVD including coronary heart disease, cerebrovascular disease, peripheral vascular disease and heart failure. They should be considered in the highest risk group for CVD and undergo assessment and reduction in risk factors accordingly.

**Evaluation and Treatment of Chronic Kidney Disease:**
• Evaluate patients’ specific type of kidney disease, co-morbid conditions, disease severity (assessed by kidney function - GFR), complications (related to the level of kidney function), risk for loss of kidney function, and risk for the development of cardiovascular disease.
• Therapy is based on the specific kidney diagnosis, prevention, diagnosis, evaluation and treatment of co-morbid conditions; measures to slow the progression of kidney damage.
• Review of patient medications should be performed at each office visit. Careful consideration should be rendered to dosages based on the level of kidney function. Assessment of potential drug interactions that can also lead to adverse effects of kidney function. If possible, therapeutic drug monitoring should be performed.
• Patients with chronic kidney disease should be referred to a nephrologist for consultation and/or co-management if there is question about preparing a clinical action plan. Patients presenting with a GFR below 30mL per minute per 1.73² should also be referred to a nephrologist.

Follow-Up:
• Patient should have an action plan based on the stage of kidney disease and the presence of other risk factors and/or co-morbidities.
• Track patient’s GFR regularly to determine the stage of disease, in accordance with the NKF Classification for Chronic Kidney Disease. Measurements of serum creatinine for estimation of GFR should be rendered at least yearly and more frequently in those patients with GFR <60mL/min/1.73m².
• Ascertain risk factors for faster versus slow GFR decline including type (diagnosis) of kidney disease, non-modifiable and modifiable factors.
• Intervene accordingly to slow progression of kidney disease in all patients with chronic kidney disease.
• Interventions that have been proven effective include:
  - Strict glucose control in diabetics
  - Strict blood pressure control
  - Angiotensin-converting enzyme inhibitor or angiotensin-2 receptor blockade with close monitoring of serum sodium and creatinine levels
• Dietary assessment and evaluation; limitation dietary protein.
• Consider lipid lowering therapy as indicated.
• Correction of anemia.
• Consider all patients with chronic kidney disease to be at high risk for cardiovascular disease including coronary artery disease and cerebrovascular, peripheral vascular disease and heart failure and should be assessed routinely for cardiovascular risk factors.

Patient Education:
• Patients should receive written management plans based on the staging of their kidney damage. The plans should include the following facets of care:
  - Assessment and management of cardiovascular and cerebrovascular risk factors.
  - Monitoring of dietary protein and/or nutrition therapy with referral to registered dietician as indicated.
  - Pharmacology education regarding medications contraindicated with kidney damage.
  - Instruct patients and their caregivers as appropriate on signs and symptoms for central and peripheral neurologic involvement.

Physician Measurement and Assessment of Compliance with Guidelines
• The percentage of members identified with diabetes and hypertension who receive an annual eGFR based on their serum creatinine levels.
Legal Disclaimer:
These clinical practice guidelines were developed to assist practitioners in making decisions about appropriate health care for specific clinical circumstances. These guidelines are not fixed protocols that must be followed, but are intended for health care professionals and providers to consider. While they identify and describe generally recommended courses of intervention, they are not presented as a substitute for the advice of the physician or other knowledgeable health care professional or provider treating the patient. Individual patients may require different treatments from those specified in a given guideline. Guidelines are not entirely inclusive or exclusive of all methods of reasonable care that can obtain/produce the same results. While guidelines can be written that take into account variations in clinical settings, resources, or common patient characteristics, they cannot address the unique needs of each patient nor the combination of resources available to a particular community or health care professional or provider. Deviations from clinical practice guidelines may be justified by individual circumstances. Thus, these guidelines must be applied based on individual patient needs and are not a substitute for the professional medical judgment of the provider of care. Revised date 8/2005.